Ikonisys SA: Terms and Conditions of Availability of Preparatory Documents for the General Meeting of September 25, 2024
September 04 2024 - 12:00PM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a
company specializing in the early and accurate detection of cancers
through a unique, fully automated solution for medical analysis
laboratories, today announces that the preparatory documents for
the General Meeting of September 25, 2024 will be made available to
the public. The meeting will be held at 2 pm at the offices of the
Jeantet law firm, 11, street Galilée - 75116 Paris.
The notice of meeting serving as a convening notice including
the agenda as well as the procedures for participating in and
voting at the Meeting was published in the Bulletin of Legal
Announcements (BALO) on August 21, 2024.
Documents and information relating to the Combined General
Meeting, as well as the single voting form, are available on the
Company's investor website, in the "Shareholders" section.
Any shareholder may obtain the documents referred to above under
the conditions set out in Articles R.225-88 and R.225-89 of the
Commercial Code by sending a written request to the Company's
registered office at 62, RUE DE CAUMARTIN, 75009 PARIS.
Shareholders may vote:
- in person on the day of the General Meeting with an admission
card;
- by post ;
- or by proxy.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to www.ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904520890/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
From Nov 2023 to Nov 2024